NASDAQ OMX

Integra LifeSciences Launches Integra® SurgiMend(TM) PRS Meshed Collagen Matrix for Breast Reconstruction in Europe

Del

 

Expands SurgiMend(TM) technology breast reconstruction product line

PLAINSBORO, N.J., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the expansion of its acellular dermal tissue matrix (ADM) product line for plastic and reconstructive surgery, including breast reconstruction in Europe, with the introduction of Integra® SurgiMend(TM) PRS Meshed.

Integra SurgiMend PRS Meshed has received CE Mark approval and expects to begin a full market release in Europe in October 2017. Integra's newest acellular dermal matrix (ADM) product was presented at the London Breast Meeting on September 7 - 9, 2017 and was extremely well-received by the surgeon delegates.

Integra SurgiMend PRS, an acellular dermal tissue matrix derived from bovine dermis, is intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes. It is specifically indicated for plastic and reconstructive surgery, including breast reconstruction. The SurgiMend PRS Meshed solution offers patients the possibility for one single-stage implant breast reconstruction post-mastectomy, instead of multiple-stage surgery.

"We believe that our product offers a real potential to reduce operating time and post-operative pain and morbidity, whilst maintaining aesthetic & functional outcomes, which are key benefits to the patient," says Lesley Whitlock, director of New Business Development, Integra Europe.

"We are proud to launch the first meshed ADM, specifically intended for breast reconstruction. It will increase the surgeon's choice for both pre- and sub-pectoral breast reconstruction using the trusted SurgiMend technology, while meeting the patient demand for one-stage pre-pectoral breast reconstruction in Europe," said Stéphane Corp, vice president, Tissue Technologies, Integra Europe.

About Integra
Integra LifeSciences is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care.  Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, and orthopedics and tissue technologies.  For more information, please visit www.integralife.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. 

CONTACT: Integra LifeSciences Holdings Company

Investors:
Michael Beaulieu
+ 1 609 750 2827
michael.beaulieu@integralife.com  

Media:
Laurene Isip (U.S.)
+ 1 609 750 7984
laurene.isip@integralife.com

Marie-Anne Girel (Europe)
+ 33 4 37 47 59 70
marie-anne.girel@integralife.com

 
 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Integra LifeSciences Holdings Corp. via Globenewswire

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

LogicBio Therapeutics to Present Preclinical Data at European Society of Gene & Cell Therapy 25th Anniversary Congress in Berlin16.10.2017 15:00Pressemelding

· Company co-founder Professor Adi Barzel, Ph.D., to present new proof-of-concept efficacy data CAMBRIDGE, Massachusetts, Oct. 16, 2017 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc., a gene-therapy company with a mission to develop cures for early-onset life-threatening diseases, announced today that its company co-founder, Dr. Adi Barzel, will present new data from its genome-editing platform during the 25th Annual European Society of Gene & Cell Therapy (ESGCT) Congress in two presentations this Wednesday in Berlin, Germany. The ESGCT will be held from October 17-20, 2017, at the bcc Berlin. Dr. Barzel will present data in multiple animal models of disease demonstrating the extended therapeutic potential of LogicBio's proprietary GeneRide(TM) platform technology. The GeneRide technology harnesses the natural power of homologous recombination to enable precise, site-specific in vivo genome editing to deliver therapeutic genetic material without th

CP Kelco Appoints Didier Viala as New President16.10.2017 15:00Pressemelding

ATLANTA, Oct. 16, 2017 (GLOBE NEWSWIRE) -- CP Kelco, a leading global producer of specialty hydrocolloid solutions, announced today that Didier Viala has been appointed President, effective October 1, 2017. Viala replaces Donald Rubright, who served as CP Kelco President since 2006 and will retire at the end of 2017. Viala has also joined the CP Kelco Board of Directors. "As a market leader supplying high-quality hydrocolloid products for a range of foods and beverages, consumer products and industrial applications, CP Kelco will continue to invest in capacity additions, new product and applications development, strategic raw material sourcing, quality and safety management, and sustainability initiatives to support our customers' innovation efforts and growth strategies," Viala said. Over the course of more than 25 years with CP Kelco and its predecessor companies, Viala held leadership roles across a broad spectrum of critical areas, including innovat

Telefonica Deploys ASSIA's GPON Expresse® Solution to optimize Fiber Broadband Performance16.10.2017 14:00Pressemelding

REDWOOD CITY, Calif., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Adaptive Spectrum and Signal Alignment, Inc. (ASSIA®). ASSIA and Telefonica announce widespread deployment of ASSIA's GPON Expresse® software across countries in South America: Argentina, Brazil, Chile, Colombia and Peru. GPON Expresse manages gigabit optical broadband networks with diagnostics for improved network performance and service delivery to Telefonica's fiber-based subscribers. GPON Expresse adds to the suite of ASSIA software products currently deployed at Telefonica in Latin America: DSL Expresse® for diagnostics and optimization of high speed DSL networks, and ClearView® for precise network analysis and recommendations for customer care agents and field technicians.  With the GPON Expresse deployment, Telefonica can now benefit from ClearView support across both copper and fiber networks.  By also incorporating ClearView support for Wi-Fi, operators can have complete end-to-end management across their ac

Concurrent Enters Definitive Agreement to Sell Content Delivery & Storage Business to Vecima Networks for $29 Million16.10.2017 14:00Pressemelding

Proposed Transaction Expected to Result in Debt Free Balance Sheet with $67 Million in Pro Forma Working Capital ATLANTA, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Concurrent Computer Corporation (NASDAQ:CCUR) has entered into a definitive agreement to sell all of the assets of its Content Delivery & Storage Business to Vecima Networks Inc. (TSX:VCM) for a base purchase price of $29 million, subject to adjustment for normalized net working capital.  Headquartered in Victoria, British Columbia, Vecima is a leading designer and manufacturer of innovative network technology solutions. The proposed transaction, which has been approved by the Board of Directors of both companies, is subject to various terms and conditions including stockholder approval from Concurrent. "Vecima believes that the rapid growth in IPTV delivery across both MVPD private CDNs and OTT providers will continue to accelerate.  Concurrent is a recognized leader in storing, protec

Fennec Announces Positive Results From Phase 3 SIOPEL 6 Study on PEDMARK(TM) (sodium thiosulfate) Presented at the 49th Congress of the International Society of Pediatric Oncology (SIOP) 2017 Meeting16.10.2017 12:00Pressemelding

Study met primary endpoint (p=0.0033) Significant reduction in cisplatin induced hearing loss without any evidence of tumour protection in patients with Standard Risk Hepatoblastoma (SR-HB) Company plans to pursue regulatory approvals with FDA and EMA RESEARCH TRIANGLE PARK, N.C., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, announced today data from its Phase 3 SIOPEL 6 study presented during the late breaker session on Saturday, October 14, 2017 at SIOP 2017 in Washington, DC. Top Line Efficacy Data The SIOPEL 6 study met its primary endpoint.  The study demonstrated that the addition of STS significantly reduces the incidence

Nexeo Solutions to Distribute Vydyne® PA66 From Ascend16.10.2017 05:05Pressemelding

Nexeo Solutions expands engineering plastics portfolio THE WOODLANDS, Texas, Oct. 15, 2017 (GLOBE NEWSWIRE) -- Nexeo Solutions, Inc. (NASDAQ:NXEO), a leader in chemicals and plastics distribution, announced today an agreement with Ascend Performance Materials to distribute their polyamide 66 injection moulding resins and compounds in Germany, Austria, Central and Eastern Europe excluding Russia. As one of the world's largest fully integrated producers of polyamide 66 resin, Ascend's manufacturing process helps ensure quality, consistency and supply security for customers. The Vydyne® PA66 grades are used in common products every day around the world, from car engines and sporting equipment to apparel and cable ties. Ascend's world-wide manufacturing facilities are vertically integrated, enabling the flexibility to respond to the expanding needs of injection moulders. Nexeo Solutions' wide product range, coupled with excellent customer and

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom